You have 9 free searches left this month | for more free features.

fingolimod

Showing 1 - 25 of 147

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Intracerebral Hemorrhage Trial (Fingolimod)

Not yet recruiting
  • Intracerebral Hemorrhage
  • Fingolimod
  • (no location specified)
Oct 17, 2023

Chemo-Induced Peripheral Neuropathy, Numbness, Pain Trial in Rochester, Columbus (Fingolimod, Fingolimod Hydrochloride,

Active, not recruiting
  • Chemotherapy-Induced Peripheral Neuropathy
  • +3 more
  • Fingolimod
  • +2 more
  • Rochester, Minnesota
  • +1 more
Jan 17, 2023

Pharmacogenetics of Liver Toxicity in Multiple Sclerosis Treated

Recruiting
  • Multiple Sclerosis
  • Genetic polymorphism
  • Measurement of fingolimod and fingolimod-phosphate concentrations
  • Caen, France
    Caen University Hospital
Aug 23, 2022

Breast Carcinoma Trial in Rochester, Columbus, Richmond (Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration)

Active, not recruiting
  • Breast Carcinoma
  • Fingolimod
  • +2 more
  • Rochester, Minnesota
  • +2 more
Jul 6, 2022

Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection Trial in Houston (Fingolimod, Placebo)

Enrolling by invitation
  • Interstitial Fibrosis
  • +6 more
  • Fingolimod
  • Placebo
  • Houston, Texas
    Houston Methodist Research Institute
Jan 23, 2023

Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))

Recruiting
  • Multiple Sclerosis
  • Clermont-Ferrand, France
    CHU Clermont-Ferrand
Jan 5, 2023

Stroke Inflammation Trial in Fuzhou (Fingolimod)

Recruiting
  • Stroke Inflammation
  • Fingolimod
  • Fuzhou, China
    The First Affiliated Hospital of Fujian Medical University
Apr 12, 2022

Generic Fingolimod in Relapsing-Remitting Multiple Sclerosis in

Recruiting
  • Relapsing-Remitting Multiple Sclerosis
  • Fingolimod
  • Alexandria, Egypt
  • +1 more
Jun 14, 2022

Diabetes, Type 2 Trial in Shenyang (Fingolimod, guideline-based treatment for DM)

Recruiting
  • Diabetes Mellitus, Type 2
  • Fingolimod
  • guideline-based treatment for DM
  • Shenyang, China
    Department of Neurology, General Hospital of Northern Theater Co
Mar 31, 2022

Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic Trial in Winston-Salem (Fingolimod 0.5 mg, Placebo, Standard of

Recruiting
  • Intracerebral Hemorrhage
  • +4 more
  • Fingolimod 0.5 mg
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest University Health Sciences
Nov 28, 2022

Impact of Fingolimod Adherence on Outcomes

Completed
  • Multiple Sclerosis
  • Fingolimod
  • East Hanover, New Jersey
    Novartis Investigational Site
Dec 15, 2021

Bioequivalence, Safety Trial in Mount-Royal (Fingolimod 0.5 mg capsules- Test drug)

Completed
  • Bioequivalence
  • Safety
  • Fingolimod 0.5 mg capsules- Test drug
  • Mount-Royal, Quebec, Canada
    Algorithme Pharma Inc.
Dec 6, 2021

Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in

Completed
  • Multiple Sclerosis
    • Aurora, Colorado
      University of Colorado Hospital
    Mar 4, 2022

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    Completed
    • Multiple Sclerosis
    • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    • Prague, Czechia
      IMPULS Endowment Fund
    Mar 7, 2023

    Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)

    Recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Fingolimod 0.5mg
    • Beijing, Beijing, China
    • +12 more
    Feb 3, 2022

    Stroke, Inflammation Trial in Hangzhou (Fingolimod)

    Withdrawn
    • Stroke
    • Inflammation
    • Fingolimod
    • Hangzhou, Zhejiang, China
      The second affiliated hospital of Zhejiang University
    Jul 15, 2021

    Relationship Between Oral DMT Burden and Adherence in MS

    Enrolling by invitation
    • Multiple Sclerosis
    • Adherence, Medication
    • Melbourne, Victoria, Australia
      Monash University
    Aug 28, 2022

    Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

    Recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +8 more
    • Eden Prairie, Minnesota
      OptumInsight
    Jan 9, 2023

    Stroke, Inflammation Trial in Hangzhou (Fingolimod, Placebo)

    Unknown status
    • Stroke
    • Inflammation
    • Fingolimod
    • Placebo
    • Hangzhou, Zhejiang, China
      The second affiliated hospital of Zhejiang University
    Jul 17, 2021

    Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)

    Recruiting
    • Multiple Sclerosis (MS)
    • Fingolimod
    • +5 more
    • Little Rock, Arkansas
    • +55 more
    Jan 13, 2023

    Natural Killer Cells in Multiple Sclerosis Patients Treated With

    Terminated
    • Relapsing-Remitting Multiple Sclerosis
      • Berlin, Germany
        Charité Universitätsmedizin Berlin
      Jul 28, 2021

      Stroke Trial (Fingolimod, )

      Not yet recruiting
      • Stroke
      • Fingolimod
      • placebo
      • (no location specified)
      Jan 17, 2021

      Multiple Sclerosis, Relapsing-Remitting Trial in Washington (NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS)

      Completed
      • Multiple Sclerosis, Relapsing-Remitting
      • NeuroQuant
      • +3 more
      • Washington, District of Columbia
        The George Washignton University
      Jan 4, 2023

      Coronavirus Disease (COVID-19) Trial in Fuzhou (Fingolimod 0.5 mg)

      Withdrawn
      • Coronavirus Disease (COVID-19)
      • Fingolimod 0.5 mg
      • Fuzhou, China
        Wan-Jin Chen
      Nov 11, 2020

      Relapsing-remitting Multiple Sclerosis Trial in Stockholm (Rituximab)

      Active, not recruiting
      • Relapsing-remitting Multiple Sclerosis
      • Stockholm, Sweden
        Fredrik Piehl
      Apr 8, 2022